The US Food and Drug Administration (FDA) has approved United States-based Sage Therapeutics' Zulresso (brexanolone) injection intended for the treatment of postpartum depression (PPD) in adult women, it was reported yesterday.
The approval was based on data from three multicenter, randomized, double-blind, parallel-group and placebo-controlled trials designed to assess the safety and effectiveness of Zulresso in women with moderate and severe PPD aged between 18 and 45 years.
The product is claimed to be the first and only medicine to have secured approval to treat PPD, which is the most common medical complication of childbirth. It is an allosteric modulator of both synaptic and extrasynaptic GABAA receptors.
The firm is planning to introduce the product in late June after scheduling by the US Drug Enforcement Administration, which is expected to take place within 90 days. It has also received PRIority Medicines (PRIME) designation for Zulresso from the European Medicines Agency (EMA).
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial